IMMUTEP Ltd
For the period ended Sep 11, 2026. Filed Sep 11, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Sep 11, 2026 · Filed Sep 11, 2026
Use the contents to explore the available documents and sections.
IMMP$3.34+24.2%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Other Programs
Other Programs
Immutep’s LAG-3 portfolio extends beyond efti. Development of IMP761, the Company’s agonist anti-LAG-3 antibody for autoimmune disease, continues in line with previously disclosed plans.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.